REVIEW

Infectious complications of endourological treatment of kidney stones: A meta-analysis of randomized clinical trials

Rawa Bapir^{1, 13}, Kamran Hassan Bhatti^{2, 13}, Ahmed Eliwa^{3, 13}, Herney Andrés García-Perdomo^{4, 13}, Nazim Gherabi^{5, 13}, Derek Hennessey^{6, 13}, Panagiotis Mourmouris^{7, 13}, Adama Ouattara^{8, 13}, Gianpaolo Perletti^{9, 10, 13}, Joseph Philipraj^{11, 13}, Alberto Trinchieri^{12, 13}, Noor Buchholz¹³

³ Department of Urology, Zagazig University, Zagazig, Sharkia, Egypt;

- ⁴ Universidad del Valle, Cali, Colombia;
- ⁵ Faculty of Medicine Algiers 1, Algiers, Algeria;
- ⁶ Department of Urology, Mercy University Hospital, Cork, Ireland;

⁷ 2nd Department of Urology, National and Kapodistrian University of Athens, Sismanoglio Hospital, Athens, Greece;

⁸ Division of Urology, Souro Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso;

⁹ Department of Biotechnology and Life Sciences, Section of Medical and Surgical Sciences, University of Insubria, Varese, Italy; ¹⁰ Faculty of Medicine and Medical Sciences, Ghent University, Belgium;

¹¹ Department of Urology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India;

- ¹² Urology School, University of Milan, Milan, Italy;
- ¹³ U-merge Ltd. (Urology for emerging countries), London-Athens-Dubai *.

* U-merge Ltd. (Urology for Emerging Countries) is an academic urological platform dedicated to facilitate knowledge transfer in urology on all levels from developed to emerging countries. U-merge Ltd. is registered with the Companies House in London/ UK. www.U-merge.com

Objective: Endourological treatment is asso-Summary ciated with a risk of postoperative febrile urinary tract infections and sepsis. The aim of this study was to review the reported rate of infectious complications in relation to the type and modality of the endourologic procedure. Methods: This systematic review was conducted in accordance with the PRISMA guidelines. Two electronic databases (PubMed and EMBASE) were searched. Out of 243 articles retrieved we included 49 studies after full-text evaluation. Results: Random-effects meta-analysis demonstrated that retrograde intrarenal surgery (RIRS) and percutaneous nephrolithotomy (PCNL) were associated with not significantly different odds of getting fever (OR = 1.54, 95% CI: 0.99 to 2.39; p = 0.06) or sepsis (OR = 1.52, 95% CI: 0.37 to 6.20, p = 0.56). The odds of getting fever were not significantly different for mini PCNL compared to standard PCNL (OR = 1.11, 95% CI: 0.85 to 1.44; p = 0.45) and for tubeless PCNL compared to standard PCNL (OR = 1.34 95% CI: 0.61 to 2.91, p = 0.47). However, the odds for fever after PCNL with suctioning sheath were lower than the corresponding odds for standard PCNL (OR = 0.37, 95% CI: 0.20 to 0.70, p = 0.002). The odds of getting fever after PCNL with perioperative prophylaxis were not different from the corresponding odds after PCNL with perioperative prophylaxis plus a short oral antibiotic course (before or after the procedure) (OR = 1.31, 95% CI: 0.71 to 2.39, p = 0.38).Conclusions: The type of endourological procedure does not appear to be decisive in the onset of infectious complications,

although the prevention of high intrarenal pressure during the procedure could be crucial in defining the risk of infectious complications.

KEY WORDS: Kidney calculi; Percutaneous nephrolithotomy; Retrograde intrarenal surgery; Ureteroscopy; Lithotripsy; Systemic inflammatory response syndrome; Sepsis; Fever; Urinary tract infection.

Submitted 15 January 2022; Accepted 1 February 2022

INTRODUCTION

Percutaneous and retrograde endourological procedures are widely used for the removal of renal stones. These treatments ensure high stone free rates and are associated with a relatively low morbidity. However, infectious complications are not uncommon in both.

After *retrograde intrarenal surgery* (RIRS), the rate of febrile urinary tract infections can range between 7.6 and 13.4% (1). Risk factors include preoperative pyuria, stone size, struvite stone composition, operating time, irrigation flow rate and volume, size of ureteral access sheath, presence of residual fragments, history of urinary tract infections, and comorbidities (2-5). The incidence of fever after percutaneous nephrolithotomy (PCNL) was reported to range between 10.4% and to 18.9%, with urosepsis in 0.9% to 4.7% of cases. Longer operating time, higher number of punctures, tract size, staghorn stone, severe preoperative hydronephrosis, preoperative stenting, history of recurrent urinary tract infection, renal failure, and type 2 diabetes were found to be risk factors (6-9).

The aim of this systematic review was to assess the reported rate of infectious complications in relation to the type of endourologic procedure, the methods used in the procedure and the antibiotic prophylaxis applied.

MATERIALS AND METHODS

This review was conducted in accordance with the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA) guidelines (10) after being registered on the PROSPERO platform (CRD42021283094). Two electronic databases (*PubMed and EMBASE*) were searched for articles published up to September 30th, 2021.

¹ Smart Health Tower, Sulaymaniyah, Kurdistan region, Iraq;

² Urology Department, HMC, Hamad Medical Corporation, Oatar;

No conflict of interest declared.

Search was performed including MeSH terms (*percutaneous nephrolithotomy*, *ureteroscopy*, *lithotripsy*, *kidney calculi*, *Systemic Inflammatory Response Syndrome*, *Sepsis*, *Fever*, *Urinary Tract Infections*) and was implemented by free-text terms (micro-percutaneous nephrolithotomy, PCNL, mini-PCNL, retrograde intrarenal surgery, flexible ureteroscopy, RIRS, FURS, ECIRS).

The following search terms were used: (percutaneous nephrolithotomy OR ureteroscopy OR lithotripsy OR micro-percutaneous nephrolithotomy OR PCNL OR mini-PCNL OR retrograde intrarenal surgery OR flexible ureteroscopy OR RIRS OR FURS OR ECIRS) AND kidney calculi AND (systemic inflammatory response syndrome OR sepsis OR fever OR urinary tract infections).

Relevant data were also hand searched by browsing various sources (e.g., reference lists from reviews and study reports, congress abstracts, www.clinicaltrials.gov, www.clinicaltrialsregister.eu, and others).

During the initial screening of the retrieved records we considered *randomized controlled trials* (RCTs), with an open-label or single/double blinded design including participants without restriction of age or gender or ethnicity, treated for renal stones with percutaneous endoscopic procedures (including standard PCNL, mini-PCNL, ultraminior micro-PCNL) and retrograde endoscopic procedures (flexible ureteroscopy or RIRS). Article reporting comparisons between *Endoscopic Combined Intrarenal Surgery*

(ECIRS) and single endoscopic procedures (both percutaneous and retrograde) were also initially examined.

In this systematic review we included articles reporting the comparison of infectious complication rates in:

1) PCNL vs RIRS, 2) standard PCNL vs miniaturized PCNL, 3) tubeless vs non tubeless PCNL, 4) PCNL or RIRS with/without use of suctioning sheath, and 5) PCNL/RIRS under different modalities of antibiotic prophylaxis.

The following outcomes were considered: fever > 38°C or sepsis according to Systemic Inflammatory Response Syndrome (SIRS) or Sequential Organ Failure Assessment (SOFA) scores.

The Systemic Inflammatory Response Syndrome (SIRS) score had been used since 1991. It is calculated based on the presence of the following criteria: temperature > 38°C or < 36°C, heart rate > 90/minute, respiratory rate > 20/minute, WBC > 12,000 or < 4,000 (11). The SOFA score was introduced by the Sepsis-3 Task Force in 2016. The quick SOFA (qSOFA) score is a simpler scoring system based on the presence of a respiratory rate ≥ 22 /min, a systolic blood pressure ≤ 100 mmHg, and altered mental status (12).


Title and abstract screening to exclude documents that did not meet the inclusion criteria were performed

independently by two authors. Controversies were resolved by a third researcher. Duplicate references were excluded and full texts of the screened articles were analyzed to confirm their inclusion in the review. A PRISMA flow diagram was drawn to illustrate the results of the study selection process (Figure 1).

Data extraction was conducted by two authors using a standardized form. The following information was obtained from each study: author(s), publication year, study design, population, intervention, rate of infectious complications (fever, SIRS, sepsis) (see *Supplementary Materials - PICO tables*). The risk of bias of randomized controlled trials was assessed using the *Risk of Bias* (RoB) 2 assessment tool as prescribed by the Cochrane Handbook (13). The quality of each study was independently assessed by two reviewers (DH and HAG-P) against pre-defined criteria in relation to the randomization process (D1), deviations from the intended interventions (D1), missing outcome data (D3), measurement of the outcome (D4) and selection of the reported result (D5). Disagreements were resolved by discussion.

The presence of risk of bias was not used as a criterion to exclude studies from this review or from meta-analysis (see *Supplementary Materials - RoB*).

Statistical analysis was performed using the RevMan5 software. Dichotomous data (presence/absence of infectious complications) and number of per-protocol or intent-to-



treat patients were extracted to calculate odds ratios (OR), confidence intervals (CI) to odds-ratios, and Z statistics (Random-effects model, Mantel-Haenszel method). Forest plots were drawn in the presence of more than three studies.

Heterogeneity was assessed by I^2 statistics, reported with 95% CIs, and interpreted as of lesser importance $(\leq 40\%)$, moderate (30%-60%), substantial (50%-90%) or considerable (\geq 75%), according to Cochrane criteria.

Summary of Findings tables for comparisons outlined in Forest plots were prepared. The quality of evidence was rated according to GRADE criteria (see Supplementary Materials - Summary of findings).

Funnel plots were drawn to assess report bias. Publication bias was assessed by visually inspecting the funnel plots (see Supplementary Materials - Publication bias). If a potential reporting bias was suspected, the Egger's regression and Begg's correlation tests were applied to assess the significance of funnel plot asymmetry and to confirm the perceived publication bias. Asymmetry tests were performed using the MetaEssentials 1 software (Rotterdam School of Management, Erasmus University, The Netherlands).

The 'trim and fill' missing study imputation approach was applied to asymmetric funnel plots and adjusted overall effect sizes were calculated.

RESULTS

From our primary search we retrieved 48 articles from PubMed, 176 from EMBASE and 19 from other sources. Title and abstract screening allowed us to select 91 articles (21 from PubMed, 62 from EMBASE and 8 from other sources), that were reduced to 76 after removal of 15 duplicates. After full-text evaluation, 27 articles were excluded (2 articles reporting about pediatric populations, 4 articles reporting data of patients which were part of studies already included in this review, 13 articles for insufficient reporting, 6 articles dealing with a topic not included in the analysis, and 2 articles reporting the results of non-randomized studies) (Table 1).

Finally, 49 studies were included in qualitative analysis (14-62), of which 39 were suitable for quantitative analysis.

Table 1.

Results of the selection process divided by topic and procedure.

	PubMed	EMBASE	Other sources	Total	Duplicates	Evaluated	Excluded	Included
RIRS vs PCNL	6	11	3	20	4	16	1	15
sPCNL vs mini	1	14	2	17	1	16	7	9
Tubeless	4	17	0	21	3	18	9	9
Sheath	2	9	0	11	2	9	5	4
Prophylaxis	8	11	3	22	5	17	5	12
Total	21	62	8	91	15	76	27	49

Reasons for exclusion	Pediatric population	Insufficient data reporting	Reporting same series	Reporting topics not included in the analysis	Not randomized
RIRS vs PCNL	1				
sPCNL vs mini		5	2		
Tubeless	1	5		2	1
Sheath			2	2	1
Prophylaxis		3		2	
Total	2	13	4	6	2

RIRS vs PCNL

We retrieved 20 articles (6 from Pubmed, 11 from EMBASE, 3 from other sources). After removal of 4 duplicates and one article involving a pediatric population, 15 studies were included in the analysis (14-28). Out of 15 studies, 11 evaluated post-operative fever (14-16, 18, 20-23, 25, 27, 28), 2 sepsis (17, 24), and 2 both post-operative fever and sepsis (19, 26).

Standard PCNL

vs mini/ultra mini/supermini/micro PCNL

We retrieved 17 articles (1 from PubMed, 14 from EMBASE, 2 from other sources). After removal of one duplicate, 16 full-text articles were evaluated.

Two articles were excluded because they reported data from the same study, and 5 more for insufficient data reporting. Finally, 8 articles were included in the analysis (29-36) and one article reporting a comparison of mini-PCNL with ultramini-PCNL (37) was considered for qualitative analysis.

Standard PCNL vs tubeless PCNL

We retrieved 21 articles (4 from PubMed, 17 from EMBASE). After removal of 3 duplicates, 18 full-text articles were evaluated.

Nine articles were excluded (one involving a pediatric population, 5 for insufficient reporting, 2 comparing tubeless PCNL within different size tracts, and 1 not randomized).

Out of the 9 articles included in the analysis, 6 articles compared tubeless with standard PCNL (38-43), 2 articles compared tubeless PCNL with tubeless PCNL with use of sealant (44, 45), and one study tubeless PCNL with and without infiltration of the tract with bupivacaine (46).

Standard PCNL/RIRS vs vacuum-assisted

We retrieved 11 articles (2 from PubMed 9 from EMBASE). After exclusion of 2 duplicates, 9 articles were included for full text evaluation: 2 were excluded because they reported data of patients which were part of studies already included in this review, 2 because they reported

> series of ureteral stones, and 1 for its retrospective design.

Out of the remaining 4 articles, 3 reported about the use of a vacuum-assisted access sheath for PCNL (47-49), and one the use of ureteral access sheaths for RIRS (50).

Perioperative prophylaxis

We retrieved 22 articles (8 from PubMed, 11 from EMBASE and 3 from other sources).

After removal of 5 duplicates, 17 articles were evaluated by full-text reading. Two articles were excluded because they were off-topic (comparison with open surgery, ureteral stones) and 3 because of incomplete reporting.

Out of the 12 remaining articles (51-62), one study compared perioperative antibiotic prophylaxis with a short course of antibiotics in patients at high risk for infectious complications (51), 5 studies (52-56) compared the effect of perioperative antibiotic prophylaxis with a single dose (or with two doses 24-48 hours apart) with a more complex strategy associating perioperative prophylaxis with a short course of antibiotic in the preoperative or postoperative period, 2 studies compared the results of perioperative prophylaxis with different antibiotics (57, 58), and 2 studies compared both perioperative prophylaxis with different antibiotics and different strategies of antibiotic prophylaxis (59, 60).

Finally, two randomized placebo-controlled studies evaluated the outcome of antibiotic prophylaxis in patients who underwent PCNL or RIRS (61, 62). was considered low in 44 studies and unclear in 5 and risk of bias in selection of the reported results was judged low in 38 studies, unclear in 10 and high in one. In total risk of bias was considered low in 10, unclear in 28 and high in 11.

Meta-analysis

RIRS vs PCNL

Random-effects meta-analysis revealed that *retrograde intrarenal surgery* (RIRS) and *percutaneous nephrolithotomy* (PCNL) were not associated with significantly different odds of getting fever (OR = 1.54, 95% CI: 0.99 to 2.39; 13 trials, 1285 participants, Z = 1.91, P = 0.06, I² = 0%) or sepsis (OR = 1.52, 95% CI: 0.37 to 6.20; 4 trials, 428 participants, Z = 0.59, P = 0.56, I²=38%) (Figures 2a, 2b).

Figure 2a, b.

а

Odds of getting fever (plot a) or sepsis (plot b) after RIRS or PCNL (plot labels: on the right: favors PCNL; on the left: favors RIRS) [explanation: the Gu trial favors PCNL because RIRS shows more febrile events: thus the Gu point is on the right: less febrile events with PCNL]

	RIRS	5	PCN	L		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-	H, Random, 95% Cl	
Agrawal 2016	2	24	2	24	4.7%	1.00 [0.13, 7.75]			
Fayad 2016	3	60	2	60	5.9%	1.53 [0.25, 9.48]			
Gu 2013	17	29	5	30	13.3%	7.08 [2.11, 23.79]			-
Jiang 2019	2	58	1	58	3.3%	2.04 [0.18, 23.09]			20
Jin 2019	4	110	6	110	11.7%	0.65 [0.18, 2.39]			
Kumar 2014	2	43	2	41	4.8%	0.95 [0.13, 7.09]			
Lee 2015	2	35	2	35	4.8%	1.00 [0.13, 7.53]	-		
Li 2016	1	35	2	35	3.3%	0.49 [0.04, 5.61]			
Mhaske 2017	4	40	2	40	6.3%	2.11 [0.36, 12.24]			
Sabnis 2013	4	35	3	35	7.9%	1.38 [0.28, 6.66]			
Wen 2016	10	34	8	34	16.7%	1.35 [0.46, 4.00]			
Zeng 2018	6	80	4	80	11.5%	1.54 [0.42, 5.68]		· · ·	
Zhang 2014	3	60	2	60	5.9%	1.53 [0.25, 9.48]			
Total (95% CI)		643		642	100.0%	1.54 [0.99, 2.39]		•	
Total events	60		41						
Heterogeneity: Tau ² =	0.00; Chi ^a	= 9.45	df = 12 (P = 0.6	6); I ^z = 0%				
Test for overall effect:	Z = 1.91 (P = 0.0	6)				0.01 0.1	1 10 RIRS PCNL	100
	RIRS		PCN	2		Odds Ratio		Odds Ratio	

b.

	RIRS	5	PCN	L		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI	
Jain 2021	7	40	0	40	17.3%	18.13 [1.00, 329.27]			-
Jin 2019	0	110	1	110	14.8%	0.33 [0.01, 8.20]	-		
Oo 2020	5	30	3	30	37.1%	1.80 [0.39, 8.32]			
Wen 2016	2	34	3	34	30.7%	0.65 [0.10, 4.13]		•	
Total (95% CI)		214		214	100.0%	1.52 [0.37, 6.20]		-	
Total events	14		7						
Heterogeneity: Tau ² =	0.77; Chi ²	= 4.84,	df = 3 (P	= 0.18); l² = 38%	; t	000		
Test for overall effect:						0	0.002	0.1 1 10 RIRS PCNL	5

Risk of bias

Of the 49 studies, 25 described methods of randomization with low risk of bias, 17 with unclear risk and 7 with high risk. We judged the risk of deviations from the intended intervention as low in 24 studies, unclear in 22 and high in 3.

Missing outcome data was judged low in 35 studies and unclear in 14. Risk of bias in measurement of outcome

Mini vs standard PCNL

The odds of getting fever were not significantly different when mini-PCNL was compared to standard-PCNL (OR = 1.11, 95% CI: 0.85 to 1.44; 8 trials, 2774 participants, Z = 0.76, P = 0.45, $I^{2} = 0\%$) (Figure 3).

A study of *Sabnis et al.*, not included in the meta-analysis compared mini-PCNL (12 F) with ultramini-PCNL (7.5 F) for treating stone of a size < 1.5 cm, demonstrat-


Figure 3.

Odds of getting fever after miniaturized PCNL (mini-PCNL) compared to standard PCNL (S-PCNL). (plot labels: on the right: favors standard PCNL; on the left: favors mini-PCNL)

	Mini PO	CNL	Standard I	PCNL		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	CI M-H, Random, 95% CI
Agrawal 2018	2	20	2	20	1.6%	1.00 [0.13, 7.89]	1
Bozzini 2020	3	88	4	44	3.0%	0.35 [0.08, 1.65]	· · · · ·
Cheng 2010	15	72	27	115	13.8%	0.86 [0.42, 1.75]	· · ·
Guddeti 2020	1	75	5	75	1.5%	0.19 [0.02, 1.66]	·
Guler 2018	1	51	0	46	0.7%	2.76 [0.11, 69.50]	· · · · · · · · · · · · · · · · · · ·
Sakr 2018	8	87	5	81	5.2%	1.54 [0.48, 4.91]	i
Tepeler 2014	1	10	0	10	0.6%	3.32 [0.12, 91.60]	
Zeng 2021	97	992	81	988	73.6%	1.21 [0.89, 1.65]	i =
Total (95% CI)		1395		1379	100.0%	1.11 [0.85, 1.44]	ı 🔶
Total events	128		124				
Heterogeneity: Tau ^a =	0.00; Chi ²	= 6.53.	df = 7 (P =	0.48); P	= 0%		
Test for overall effect:	Z = 0.76 (P = 0.4	5)				0.01 0.1 1 10 100 Mini PCNL Standard PCNL

Figure 4.

Odds of getting fever after tubeless PCNL (TL-PCNL) compared with standard PCNL (S-PCNL) (plot labels: on the right: favors S-PCNL; on the left: favors TL-PCNL)



ing comparable rates of postoperative sepsis (0/30 vs 1/30) (37).

Tubeless PCNL vs standard PCNL

The odds for fever were not significantly different when tubeless-PCNL was compared to standard-PCNL (OR = $0.75\ 95\%$ CI: 0.34 to 1.63; 6 trials, 505 participants, Z = 0.73, P = 0.47, I^A2 = 0%) (Figure 4).

Two studies, not included in the pooled analysis, compared the rate of infectious complications after tubeless PCNL vs. tubeless PCNL with use of sealant.

Shah et al (44) showed similar rates of fever after tubeless PCNL with or without sealant (1/32 vs 2/31). Similar results were obtained by *Titaram et al.* (45) with similar rates of fever (19/41 vs 15/41, P = 0.20), lower rate of SIRS with use of sealant (but one case of sepsis versus none).

Another study compared the results of tubeless PCNL with or without infiltration with bupivacaine (rate of fever 7/46 vs 6/23, P = 0.49)(46).

PCNL/RIRS with suctioning sheath vs standard PCNL

The odds of getting fever for PCNL with suctioning sheath were significantly lower than the odds calculated for standard PCNL using a normal Amplatz sheath (OR =

0.37, 95% CI: 0.20 to 0.70; 3 trials, 351 participants, Z = 3.10, P = 0.002, I^2 = 0%) (Figure 5).

A single randomized trial not included in the meta-analysis, evaluated the risk of getting fever after RIRS with the use of suctioning sheath compared to the standard procedure. *Eisner et al.* (50) presented the results of a randomized trial including 20 patients: no infectious complication was observed in the group treated with aspiration through the access sheath, while one patient in the control group had a urinary tract infection.

Antibiotic prophylaxis (comparison with placebo)

Two studies were retrieved and not pooled, as they compared different antibacterial agents with placebo (61, 62). A multicentre randomized trial (61) compared the result of preoperative prophylaxis in PCNL with a single dose of cefotaxime (1 gr) with placebo. The rate of postoperative bacteriuria was lower in patients treated with cefotaxime although the difference was not statistically significant, likely due to the low number of patients treated with PCNL included in the study. Similarly, clinical data about the rate of postoperative fever and urinary tract infection were not available because the data relative to PCNL were aggregated with those of ureterorenoscopy.

A study presented the results of preoperative prophylaxis

Figure 5.

Odds of getting fever after PCNL with suctioning sheath (PCNL + SS) compared with standard PCNL (S-PCNL) (plot labels: on the right: favors S-PCNL; on the left: favors PCNL + SS).

	Suctioning s	heath	Standard	PCNL		Odds Ratio	Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Rand	form, 95% CI	
Huang 2016	10	91	25	91	60.0%	0.33 [0.15, 0.73]			
Lai 2020	5	38	8	38	25.9%	0.57 [0.17, 1.93]		-	
Zhong 2021	2	46	6	47	14.1%	0.31 [0.06, 1.63]		+	
Total (95% CI)		175		176	100.0%	0.37 [0.20, 0.70]	+		
Total events	17		39						
Heterogeneity: Tau ² =	0.00; Chi ² = 0.6	1, df = 2	(P = 0.74); I	2 = 0%			1001 01	1 10	100
Test for overall effect:	Z = 3.10 (P = 0		0.01 0.1 Suctioning sheath	1 10 Standard PCNL	100				

of RIRS with ciprofloxacin compared with placebo (62). The rate of RIRS after placebo (9.9%) was not significantly different from the rate assessed following treatment with one (4.9%) or two doses of ciprofloxacin (4.2%). However, a subgroup analysis demonstrated a significantly higher risk of getting SIRS in patients who received placebo for treatment of stones > 200 mm² compared to patients who received ciprofloxacin (18% vs single dose 4.3%, P = 0.036; vs two doses 5.5%, P = 0.044).

Antibiotic prophylaxis (comparison of antibiotics)

Four studies were retrieved and not pooled, as they compared different antibacterial agents administered according to different treatment protocols (57-60).

Song et al. (57) administered to patients who underwent PCNL a three-day course of oral fosfomycin (3 g/day) vs. intravenous cefuroxime (3 g/day). Fosfomycin proved to be more effective than cefuroxime, exerting a high antibacterial effect on pathogens localized in the stone, thus reducing the probability of infection. Postoperative fever was observed in 7/31 patients in the experimental group compared to 9/30 in the control group (p > 0.05) but SOFA score was > 2 in 3/31 versus 10/30 (p < 0.05).

Seyrek et al. (58) did not observe significant differences in the risk of getting SIRS after PCNL in patients treated with sulbactam-ampicillin versus cefuroxime (13.7 vs 17.7%, P = 0.44), though one patient in the sulbactamampicillin died of septic shock. Similarly, *Taken et al.* (59) observed no difference in the rate of SIRS following PCNL in patients treated with ceftriaxone (23.3%) or cefazoline (12.5%) (P = 0.264). Finally, *Demirtas et al.* (60) found no difference in the rate of SIRS after PCNL between ciprofloxacin (15.5%) and ceftriaxone (8.8% P = 0.52).

Perioperative vs perioperative

plus additional short antibiotic prophylaxis

Seven studies reported the results of the comparison of perioperative antibiotic prophylaxis versus perioperative prophylaxis associated with prolonged oral administration of antibiotics in patients who underwent PCNL for stones. Patients were deemed to be at low risk for infectious complications (negative preoperative urine culture, absence of hydronephrosis). Two studies (*Seyrek* 2012 and *Demirtas* 2012) (58, 60) included data about the use of two different antibiotics, data were pooled separately. The odds for fever after PCNL with perioperative prophylaxis were not different than after PCNL with perioperative prophylaxis plus a short oral antibiotic course (before or after the procedure) (OR = 0.76, 95% CI: 0.42 to 1.40; 9 trials, 720 participants, Z = 0.87, P = 0.38, $I^{A} = 53\%$) (Figure 6).

A study (not included in the meta-analysis) (51) compared the outcome of 2 days vs. 7 days of preoperative antibiotics in patients at moderate-to-high risk for sepsis undergoing percutaneous nephrolithotomy. The sepsis rates were not different between treatment arms on uni-

Figure 6.

Odds of getting fever after PCNL with perioperative prophylaxis (PP) compared with PCNL with perioperative prophylaxis plus a short oral antibiotic course (PP + SOC)(plot labels: on the right: favors perioperative; on the left: favors PP + SOC).

	Short oral o	ourse	Perioper	ative		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Bag 2011	9	48	26	53	14.7%	0.24 [0.10, 0.59]	
Chew 2018	6	43	5	43	11.1%	1.23 [0.35, 4.39]	-
Demirtas 2012	4	15	3	30	8.3%	3.27 [0.63, 17.09]	
Demirtas 2012b	2	15	2	30	6.1%	2.15 [0.27, 17.02]	
Dogan 2002	8	38	9	43	12.9%	1.01 [0.35, 2.94]	
Mariappan 2006	7	52	18	46	13.7%	0.24 [0.09, 0.65]	
Seyrek 2012	4	31	9	64	11.2%	0.91 [0.26, 3.21]	
Seyrek 2012b	4	32	13	64	11.6%	0.56 [0.17, 1.88]	
Tuzel 2013	6	37	4	36	10.4%	1.55 [0.40, 6.02]	
Total (95% CI)		311		409	100.0%	0.76 [0.42, 1.40]	+
Total events	50		89				
Heterogeneity: Tau ^a =	0.44; ChP = 16	5.98, df =	8 (P = 0.0	(3); I [#] = !	53%		0.01 0.1 1 10 100
Test for overall effect:	Z = 0.87 (P =	0.38)		1000			0.01 0.1 1 10 100 Short oral course Perioperative

Publication bias analysis

Figure 1 a-f (see *Supplementary Materials - Publication bias analysis*) shows the funnel plots relative to the 6 pooled analyses performed in this systematic review.

Table 1 (Supplementary Materials - Publication bias analysis) shows the significance values of the Begg's and Egger's asymmetry tests.

The only pooled analysis showing significant asymmetry (Egger's P = 0.011, Begg's P = 0.004) was the one comparing perioperative prophylaxis vs. perioperative prophylaxis plus an additional short antibiotic prophylaxis. The "Trim-and-fill" strategy imputed two missing studies to the asymmetric funnel plot. The adjusted odds ratio of the funnel plot including the imputed missing studies was 0.62 (95% CI: 0.31 to 1.28). Thus, despite the addition of two imputed studies, the odds ratio for this comparison remains not significant.

Summary of findings

Tables 1 a-e (*Supplementary Materials - Summary of findings*) present the summary of the findings of the meta-analyses, also including an evaluation of the quality of the evidence, performed according to GRADE criteria.

The quality of the evidence was rated as low for the comparisons (i) PCNL with suctioning sheath vs. standard PCNL, and (ii) PCNL with simple perioperative antibiotic prophylaxis (PAP) plus a short oral antibiotic course vs. PCNL with simple PAP. The reasons for downgrading the former were risk of bias (one point) and imprecision due to the low number of participants (one point). The reasons for downgrading the latter were risk of bias (one point) and publication bias (one point). The quality of the remaining evidence was rated as moderate, mainly due to the presence of risk of bias (one point).

DISCUSSION

Endourological treatment of kidney stones represents a considerable improvement in the management of nephrolithiasis, thanks to the reduction of morbidity and the minimal surgical impact on the urinary tract.

The complications associated with this form of treatment are relatively infrequent, though serious bleeding and infectious complications can be observed.

PCNL and RIRS are treatment modalities that have specific indications. However, the choice of a specific procedure is based on the experience of the operating surgeon and sometimes on the patient's preferences. In fact, kidney stones smaller than 20 mm can alternatively be treated with percutaneous or retrograde intracorporeal lithotripsy (63). In this case, the risk of complications should be taken into consideration when choosing between the two forms of treatment.

Retrograde and percutaneous renal stone treatment can affect the risk of infectious complications in different ways.

Flexible ureteroscopy can increase intrarenal pressure in relation (i) to type and rate of irrigation, or (ii) to the use and size of ureteral sheaths promoting the anterograde outflow of irrigation fluid. The increase in pressure within the urinary tract can cause an intratubular reflux of urine, with increased risk of infectious complications.

Percutaneous treatment does not generally involve a major increase of fluid pressure in the urinary tract, but it can cause greater local trauma and extravasation of irrigating fluid.

Previous meta-analyses have compared the results of percutaneous nephrolithotomy with the outcomes of retrograde intrarenal surgery for the treatment of kidney stones. However, the risk for infectious complications was not included in such analyses.

Zheng et al. (64) found no difference in the rate of postoperative fever (RR = 0.95, P = 0.85) between RIRS and PCNL. More recently, *Chen et al.* (65) reviewed 11 studies showing that the rate of postoperative fever or infection was not significantly different in the patients treated with PCNL compared to those treated with RIRS (RR = 1.26, P = 0.29).

Our study included only 5 of the 11 studies considered by *Chen et al.* because we limited our search to randomized controlled studies. Furthermore, we found and included in the analysis 10 additional randomized studies. However, we were not able to demonstrate a significant superiority of one endourological procedure over the other with regards to the risk of postoperative fever or sepsis. However, we observed a trend for a higher risk of fever after RIRS (OR = 1.54, 95% CI: 0.99 to 2.39).

It should be highlighted that most comparative studies had as a primary endpoint the evaluation of stone-free status after treatment rather than the occurrence of infectious complications.

Based on the results of our meta-analyses, the choice of the procedure would not seem to be a relevant factor for infectious complications after treatment.

However, the risk of infectious complications could depend on how PCNL and RIRS are performed. In our analysis, we were able to examine the impact of certain treatment procedures on the risk of infection. For PCNL, we considered the effect of the diameter of the scope and of the indwelling time of the nephrostomy after the procedure. For both PCNL and RIRS we considered the impact of the use of a suction system for the irrigating fluid and the use of different methods of antibiotic prophylaxis.

Unfortunately, it was not possible to evaluate other characteristics of the interventions - such as prolonged operating time (> 1 hour), type and rate of irrigation, use of sheath and pre-operative stenting (for RIRS) - due to the lack of information within the reports of the studies included in the analysis.

The comparison of standard PCNL with miniaturized PCNL including mini-PCNL, ultramini-PCNL, and micro-PCNL showed no significant difference in the odds for infectious complications despite a higher potential intra-renal pressure with the latter two.

The benefits of reduced trauma due to the smaller diameter of the scope could be counteracted by lesser control of intrarenal pressure associated with miniaturized procedures. In fact, a review on the evidence related to intrarenal pressures generated during percutaneous procedures found that standard PCNL is associated with the lowest pressure values. On the contrary, pressure values during mini-PCNL can be decreased by using the vacuum-cleaner effect, but pressure might still be uncontrolled during micro- and ultra-mini PCNL procedures (66).

We also found that avoidance of nephrostomy drainage in the postoperative period is not associated with an increased risk of infection after a standard procedure.

The use of suction systems through the access sheath seems to reduce the risk of infection, since in addition to the improved clearance of fragments after lithotripsy, it allows the intrarenal pressures to be controlled and kept in the lower range.

Antibiotic prophylaxis to prevent the onset of infectious complications after endourological stone treatments is widely used although only limited evidence from RCTs was retrieved (67).

Extension of oral antibiotic administration after intravenous perioperative prophylaxis, or administration of a course of antibiotic treatment in the days prior to surgery, does not seem to reduce the risk of infection in patients with low risk of infectious complications, (i.e., patients with negative preoperative urine culture and absence of hydronephrosis and urinary catheters).

However, in a study that considered patients with moderate/high risk of infectious complications, administration of a 10-day course of oral nitrofurantoin before the procedure in addition to intraoperative prophylaxis was shown to reduce the risk of infectious complications after PCNL.

EAU guidelines (63) state that there is no "*clear-cut evidence*" for prevention of infection following ureterorenoscopy and percutaneous stone removal, although a matched case control study demonstrated the efficacy of antibiotic prophylaxis to reduce infectious complications after PCNL in patients with negative baseline culture (68). Another study showed that a single dose administration was found sufficient to prevent post-ureteroscopic infections (69).

In conclusion, infectious complications after endourological treatment of kidney stones appear to depend (i) on the characteristics of the stone, on the patients' urinary tract, and on the patients' comorbidities.

The choice of a specific procedure for kidney stone treatment does not appear to be decisive for the onset of infectious complications, although the prevention of high intrarenal pressures during the procedure appears to be crucial in defining the risk of infectious complications. High intrarenal pressure depends on the modality of irrigation and on the use of the ureteral sheaths and suction systems to facilitate the outflow of urine. Antibiotic prophylaxis should be tailored to the characteristics of the stone and of the urinary tract, the history of the patient (comorbidities, previous UTI episodes) and the course of the procedure (operative time, method and volume of irrigation).

In high-risk cases, prudence is recommended, avoiding prolonged operating times, and administering antibiotic treatment before the procedure in adjunct to perioperative prophylaxis.

REFERENCES

1. Kim DS, Yoo KH, Jeon SH, Lee SH. Risk factors of febrile urinary tract infections following retrograde intrarenal surgery for renal stones. Medicine (Baltimore). 2021; 100:e25182.

2. Fan S, Gong B, Hao Z, et al. Risk factors of infectious complications following flexible ureteroscope with a holmium laser: a retrospective study. Int J Clin Exp Med 2015; 8:11252-9.

3. Zhong W, Leto G, Wang L, et al. Systemic inflammatory response syndrome after flexible ureteroscopic lithotripsy: a study of risk factors. J Endourol 2015; 29:25-8.

4. Berardinelli F, De Francesco P, Marchioni M, et al. Infective complications after retrograde intrarenal surgery: a new standardized classification system. Int Urol Nephrol. 2016; 48:1757-1762.

5. Dybowski B, Bres-Niewada E, Rzeszutko M, et al. Risk factors for infectious complications after retrograde intrarenal surgery - a systematic review and narrative synthesis. Cent European J Urol. 2021; 74:437-445.

6. Michel MS, Trojan L, Rassweiler JJ. Complications in percutaneous nephrolithotomy. Eur Urol. 2007; 51:899-906.

7. Rivera M, Viers B, Cockerill P, et al. Pre- and postoperative predictors of infection-related complications in patients undergoing percutaneous nephrolithotomy. J Endourol. 2016; 30:982-6.

8. de la Rosette J, Assimos D, Desai M, et al. The clinical research office of the endourological society percutaneous nephrolithotomy global study: Indications, complications, and outcomes in 5803 patients. J Endourol. 2011; 25:11-7.

9. Kumar GM, Nirmal KP, Kumar GS. Postoperative infective complications following percutaneous nephrolithotomy. Urol Ann. 2021; 13:340-345.

10. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.

11. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101:1644-55.

12. Singer M, Deutschman CS, Seymour CW, et al. 292 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315: 801-10.

13. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366:14898.

14. Agrawal MS, Mishra D. Minimally-invasive percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of medium sized (10-20 mm) renal calculi-a prospective study J Endourol 2016; 30 (Supplement 2):A204-A205.

15. Fayad AS, Elsheikh MG, Ghoneima W. Tubeless mini-percutaneous nephrolithotomy versus retrograde intrarenal surgery for lower calyceal stones of ≤ 2 cm: A prospective randomised controlled study. Arab J Urol 2017; 15: 36-41.

16. Gu XJ, Lu JL, Xu Y. Treatment of large impacted proximal ureteral stones: randomized comparison of minimally invasive percutaneous antegrade ureterolithotripsy versus retrograde ureterolithotripsy. World J Urol. 2013; 31:1605-1610.

17. Jain M, Manohar C, Nagabhushan M, Keshavamurthy R. A comparative study of minimally invasive percutaneous nephrolithotomy and retrograde intrarenal surgery for solitary renal stone of 1-2 cm Urol Ann 2021; 13:226-231. 18. Jiang K, Chen H, Yu X, et al. The "all-seeing needle" micro-PCNL versus flexible ureterorenoscopy for lower calyceal stones of ≤ 2 cm. Urolithiasis 2019; 47:201-206

19. Jin L, Yang B, Zhou Z, Li N. Comparative efficacy on flexible ureteroscopy lithotripsy and miniaturized percutaneous nephrolithotomy for the treatment of medium-sized lower-pole renal calculi. J Endourol. 2019; 33:914-919.

20. Kumar A, Kumar N, Vasudeva P, et al. A prospective, randomized comparison of shock wave lithotripsy, retrograde intrarenal surgery and miniperc for treatment of 1 to 2 cm radiolucent lower calyceal renal calculi: a single center experience. J Urol. 2015; 193:160-164.

21. Lee JW, Park J, Lee SB, et al. Mini-percutaneous nephrolithotomy vs retrograde intrarenal surgery for renal stones larger than 10 mm: a prospective randomized controlled trial. Urology 2015; 86:873-877.

22. Li JW, Wang F, Cai FZ, Gao HZ. Staged retrograde flexible ureteroscopic lithotripsy versus miniaturized percutaneous nephrolithotomy for renal stones of 2-4 cm in diameter: a randomized controlled trial. Nan Fang Yi Ke Da Xue Xue Bao. 2016; 36:1672-1676.

23. Mhaske S, Singh M, Mulay A, et al. Miniaturized percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of renal stones with a diameter < 15 mm: A 3-year open-label prospective study. Urol Ann. 2018; 10:165-169.

24. Oo SM. Outcomes of minipercutaneous nephrolithotomy versus retrograde intrarenal surgery in lower pole renal stone. Int J Urol. 2020; 27(Suppl 1):40.

25. Sabnis RB, Ganesamoni R, Doshi A, et al. Micropercutaneous nephrolithotomy (microperc) vs retrograde intrarenal surgery for the management of small renal calculi: a randomized controlled trial. BJU Int. 2013; 112:355-61.

26. Wen J, Xu G, Du C, Wang B. Minimally invasive percutaneous nephrolithotomy versus endoscopic combined intrarenal surgery with flexible ureteroscope for partial staghorn calculi: A randomised controlled trial. Int J Surg. 2016; 28:22-27.

27. Zeng G, Zhang T, Agrawal M, et al. Super-mini percutaneous nephrolithotomy (SMP) vs retrograde intrarenal surgery for the treatment of 1-2 cm lower-pole renal calculi: an international multicentre randomised controlled trial. BJU International. 2018; 122:1034-1040.

28. Zhang H, Hong TY, Li G, et al. Comparison of the efficacy of ultra-mini PCNL, flexible ureteroscopy, and shock wave lithotripsy on the treatment of 1-2 cm lower pole renal calculi. Urol Int. 2019; 102:153-159.

29. Agrawal M, Mishra D. Minimally-invasive percutaneous nephrolithotomy versus conventional percutaneous nephrolithotomy for treatment of large sized (20-30 mm) renal calculi-a prospective study. J Endourol. 2018; 32(Suppl2):A59-A60.

30. Bozzini G, Aydogan TB, Müller A, et al. A comparison among PCNL, Miniperc and Ultraminiperc for lower calyceal stones between 1 and 2 cm: A prospective, comparative, multicenter and randomised study. BMC Urology. 2020; 20:1.

31. Cheng F, Yu W, Zhang X, et al. Minimally invasive tract in percutaneous nephrolithotomy for renal stones. J Endourol. 2010; 24:1579-82.

32. Guddeti RS, Hegde P, Chawla A, et al. Super-mini percutaneous nephrolithotomy (PCNL) vs standard PCNL for the management of renal calculi of < 2 cm: a randomised controlled study. BJU Int. 2020; 126:273-279.

33. Güler A, Erbin A, Ucpinar B, et al. Comparison of miniaturized percutaneous nephrolithotomy and standard percutaneous nephrolithotomy for the treatment of large kidney stones: a randomized prospective study. Urolithiasis. 2019; 47:289-295.

34. Sakr A, Salem E, Kamel M, et al. Minimally invasive percutaneous nephrolithotomy vs standard PCNL for management of renal stones in the flank-free modified supine position: single-center experience. Urolithiasis. 2017; 45:585-589.

35. Tepeler A, Akman T, Silay MS, et al. Comparison of intrarenal pelvic pressure during micro-percutaneous nephrolithotomy and conventional percutaneous nephrolithotomy. Urolithiasis. 2014; 42:275-279.

36. Zeng G, Cai C, Duan X, et al. Mini percutaneous nephrolithotomy is a noninferior modality to standard percutaneous nephrolithotomy for the management of 20-40 mm renal calculi: a multicenter randomized controlled trial. Eur Urol. 2021; 79:114-121.

37. Sabnis R., Ganpule A., Desai M. Is there any rationale of preferring ultraminiperc (MIP S) over miniperc (MIP M)?Prospective randomized study. J Endourol. 2016; 30(Suppl2):A376-A377.

38. Agrawal MS, Agrawal M, Gupta A, et al. A randomized comparison of tubeless and standard percutaneous nephrolithotomy. J Endourol. 2008; 22:439-442.

39. Bhat S, Lal J, Paul F. A randomized controlled study comparing the standard, tubeless, and totally tubeless percutaneous nephrolithotomy procedures for renal stones from a tertiary care hospital Indian J Urol. 2017; 33:310-314.

40. Istanbulluoglu MO, Ozturk B, Gonen M, et al. Effectiveness of totally tubeless percutaneous nephrolithotomy in selected patients: A prospective randomized study. Int Urol Nephrol. 2009; 41:541-545.

41. Lu Y, Ping J-G, Zhao X-J, et al. Randomized prospective trial of tubeless versus conventional minimally invasive percutaneous nephrolithotomy. World J Urol. 2013; 31:1303-1307.

42. Mishra S, Sabnis RB, Kurien A, et al. Questioning the wisdom of tubeless percutaneous nephrolithotomy (PCNL): a prospective randomized controlled study of early tube removal vs tubeless PCNL. BJU Int. 2010; 106:1045-8.

43. Moosanejad N, Firouzian A, Hashemi SA, et al. Comparison of totally tubeless percutaneous nephrolithotomy and standard percutaneous nephrolithotomy for kidney stones: A randomized, clinical trial. Braz J Med Biol Res. 2016; 49:e4878.

44. Shah HN, Hegde S, Shah JN, et al. A prospective, randomized trial evaluating the safety and efficacy of fibrin sealant in tubeless percutaneous nephrolithotomy. J Urol 2006; 176:2488-2493.

45. Titaram S, Nualyong C, Taweemonkongsap T, et al. The impact of gelatin-sealant in the access tract after tubeless percutaneous nephrolithotomy: A randomized controlled trial. J Med Ass Thai. 2017; 100(Suppl2):S132-S137.

46. Mankongsrisuk T, Nualyong C, Tantiwong A, et al. Efficacy of nephrostomy tract infiltration with bupivacaine before and after tubeless percutaneous nephrolithotomy: A randomized control study. J Med Ass Thai 2017; 100(Suppl2):S138-S143.

47. Huang J, Song L, Xie D, et al. A Randomized Study of Minimally Invasive Percutaneous Nephrolithotomy (MPCNL) with the aid of a patented suctioning sheath in the treatment of renal calculus complicated by pyonephrosis by one surgery. BMC Urol. 2016; 16:71.

48. Lai D, Xu W, Chen M, et al. Minimally invasive percutaneous nephrolithotomy with a novel vacuum-assisted access sheath for obstructive calculous pyonephrosis: a randomized study. Urol J. 2020; 17:474-479.

49. Zhong W, Wen J, Peng L, Zeng G. Enhanced super-mini-PCNL (eSMP): low renal pelvic pressure and high stone removal efficiency in a prospective randomized controlled trial. World J Urol. 2021; 39:929-934.

50. Eisner B, Agrawal S, Desai M, et al. Initial human experience with a novel stone aspiration device used during ureteroscopic lithotripsy for renal stones. J Urol. 2020; 203(Suppl4):e211.

51. Sur RL, Krambeck AE, Large T, et al. A randomized controlled trial of preoperative prophylactic antibiotics for percutaneous nephrolithotomy in moderate to high infectious risk population: a report from the EDGE consortium. J Urol. 2021; 205:1379-1386.

52. Bag S, Kumar S, Taneja N, et al. One week of nitrofurantoin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: A prospective controlled study. Urology. 2011; 77:45-49.

53. Chew BH, Miller NL, Abbott JE, et al. A randomized controlled trial of preoperative prophylactic antibiotics prior to percutaneous nephrolithotomy in a low infectious risk population: a report from the EDGE consortium. J Urol. 2018; 200:801-808.

54. Dogan HS, Sahin A, Cetinkaya Y, et al. Antibiotic prophylaxis in percutaneous nephrolithotomy: prospective study in 81 patients. J Endourol. 2002; 16:649-653.

55. Mariappan P, Smith G, Moussa SA, Tolley DA. One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. BJU Int. 2006; 98:1075-9.

56. Tuzel E, Aktepe OC, Akdogan B. Prospective comparative study of two protocols of antibiotic prophylaxis in percutaneous nephrolithotomy. J Endourol. 2013; 27:172-6.

57. Song F, Liu C, Zhang J, et al. Antibacterial effect of Fosfomycin tromethamine on the bacteria inside urinary infection stones. Int Urol Nephrol. 2020; 52:645-654.

58. Seyrek M, Binbay M, Yuruk E, et al. Perioperative prophylaxis for percutaneous nephrolithotomy: randomized study concerning the drug and dosage. J Endourol. 2012; 26:1431-6.

59. Taken K., Asik A., Eryilmaz R., et al. Comparison of ceftriaxone and cefazolin sodium antibiotic prophylaxis in terms of SIRS/urosepsis rates in patients undergoing percutaneous nephrolithotomy. J Urol Surg. 2019; 6:111-117.

60. Demirtas A, Yildirim YE, Sofikerim M, et al. Comparison of infection and urosepsis rates of ciprofloxacin and ceftriaxone prophylaxis before percutaneous nephrolithotomy: a prospective and randomised study. Scientific World Journal. 2012; 2012:916381.

61. Fourcade RO. Antibiotic prophylaxis with cefotaxime in endoscopic extraction of upper urinary tract stones: a randomized study. The Cefotaxime Cooperative Group. J Antimicrob Chemother. 1990; 26(suppl A):77-83.

62. Zhao Z, Fan J, Sun H, et al. Recommended antibiotic prophylaxis regimen in retrograde intrarenal surgery: evidence from a randomised controlled trial. BJU Int. 2019; 124:496-503.

63. Türk C, Neisius A, Petrik A, et al. EAU Guidelines on Urolithiasis. Retrieved from: https://uroweb.org/guideline/urolithiasis/ Accessed on 30th December 2021.

64. Zheng C, Xiong B, Wang H, et al. Retrograde intrarenal surgery versus percutaneous nephrolithotomy for treatment of renal stones >2 cm: a meta-analysis. Urol Int. 2014; 93:417-24.

65. Chen Y, Wen Y, Yu Q, et al. Percutaneous nephrolithotomy versus flexible ureteroscopic lithotripsy in the treatment of upper urinary tract stones: a meta-analysis comparing clinical efficacy and safety. BMC Urol. 2020; 20:109. 66. Tokas T, Skolarikos A, Herrmann TRW, Nagele U; Training and Research in Urological Surgery and Technology (T.R.U.S.T.)-Group. Pressure matters 2: intrarenal pressure ranges during upper-tract endourological procedures. World J Urol. 2019; 37:133-142.

67. Mrkobrada M, Ying I, Mokrycke S, et al. CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J. 2015; 9:13-22.

68. Gravas S,, et al. Postoperative infection rates in low risk patients undergoing percutaneous nephrolithotomy with and without antibiotic prophylaxis: a matched case control study. J Urol. 2012; 188:843-7.

69. Chew BH, Flannigan R, Kurtz M, et al. A single dose of intraoperative antibiotics is sufficient to prevent urinary tract infection during ureteroscopy. J Endourol. 2016; 30:63-8.

Correspondence

Rawa Bapir

Dr.rawa@yahoo.com Smart Health Tower, Sulaymaniyah, Kurdistan region, Iraq Kamran Hassan Bhatti

kamibhatti92@gmail.com

Urology Department, HMC, Hamad Medical Corporation, Qatar.

Ahmed Eliwa

ahmedeliwafarag@gmail.com Department of Urology, Zagazig University, Zagazig, Sharkia, Egypt

Herney Andrés García-Perdomo herney.garcia@correounivalle.edu.co Universidad del Valle, Cali, Colombia

Nazim Gherabi ngherabi@gmail.com

Faculty of Medicine Algiers 1, Algiers, Algeria

Derek Hennessey derek.hennessey@gmail.com

Department of Urology, Mercy University Hospital, Cork, Ireland

Panagiotis Mourmouris thodoros13@yahoo.com

^{2nd} Department of Urology, National and Kapodistrian University of Athens, Sismanoglio Hospital, Athens, Greece

Adama Ouattara

adamsouatl@hotmail.com Division of Urology, Souro Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso

Gianpaolo Perletti

Gianpaolo.perletti@uninsubria.it

Department of Biotechnology and Life Sciences, Section of Medical and Surgical Sciences, University of Insubria, Varese, Italy

Joseph Philipraj

josephphilipraj@gmail.com

Department of Urology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India

Alberto Trinchieri (Corresponding Author)

alberto.trinchieri@gmail.com

Urology School, University of Milan, Milan, Italy

Noor Buchholz

noor.buchholz@gmail.com

Scientific Office, U-merge Ltd., Athens, Greece